Molecular Testing and Evolving Treatment Strategies in HR+/HER2– Advanced Breast Cancer

Hope S. Rugo, MD, breaks down the implications of data from SERENA-6 for the management of emergent ESR1-mutant, HR–positive breast cancer.

Hope S. Rugo, MD, discusses quality of life data from the phase 3 SERENA-6 study.

Sara M. Tolaney, MD, MPH, discusses the value of incorporating ctDNA monitoring of ESR1 mutations into routine management for HR-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the ideal time for patients with HR-positive breast cancer to undergo genetic testing for ESR1 mutations.

Erika P. Hamilton, MD, discusses the current role of CDK4/6 inhibitors and evolving targeted therapies in advanced HR-positive, HER2-negative breast cancer.

Erika P. Hamilton, MD, discusses how mutational profiles inform the management of HR-positive breast cancer after progression on a prior CDK4/6 inhibitor.